English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Graves' disease is a genetically induced autoimmune disorder characterized by hyperthyroidism due to circu- lating thyroid stimulating hormone (TSH) receptor autoantibodies (TRAb) with thyroid stimulating activity (1). Graves' disease is the most common cause of hyperthyroidism, which has an estimated prevalence in iodine sufficient areas of 20/1000 females and 2.3/ 1000 males (2). It is most common in females between the ages of 20 and 50 years, but it may occur at any age. The laboratory diagnosis of Graves' disease is based on the finding of high serum thyroid hormone and undetectable serum TSH concentrations associated with circulating thyroglobulin and thyroperoxidase anti- bodies. TRAb is detectable in almost 90% of patients, but usually it is not needed for the diagnosis. Radio- isotope scan of the thyroid shows a diffuse and homogeneous radionuclide uptake. Treatment strategies for Graves' hyperthyroidism include medical therapy with antithyroid drugs (ATD) or thyroid ablation with 131I or surgery. ATD, mainly thionamides, inhibit thyroid hormone synthesis by

Grey scale thyroid ultrasonography in the evaluation of patients with Graves' disease